D. Braguer

D. Braguer, Y. Berland, P. Brunet, 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth.

I. Alves, R. Marquant, S. Sagan, 2014, Biochimica et biophysica acta.

The in vitro effect of some nitroimidazoles on microtubule formation.

D. Braguer, V. Peyrot, M. Bendahmane, 1984, Biochemical pharmacology.

Inhibition in vitro of the polymerization of tubulin by uremic middle molecules: corrective effect of isaxonine.

D. Braguer, C. Durand, A. M. Chauvet-monges, 1983, Clinical nephrology.

Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G(1).

D. Braguer, J. Marvaldi, F. Fouchier, 2000, European journal of pharmacology.

Calcium channel blockers correct in vitro mitochondrial toxicity of cellulose acetate.

D. Braguer, Y. Berland, P. Brunet, 1997, Kidney international.

Microtubule-targeted agents: when mitochondria become essential to chemotherapy.

A. Savry, M. Carré, A. Rovini, 2011, Biochimica et biophysica acta.

Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells.

E. Pasquier, D. Braguer, C. Briand, 2005, Cancer research.

EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis

H. Lane, A. Sergé, D. Figarella-Branger, 2020, Oncotarget.

Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells

H. Kovacic, M. Carré, D. Braguer, 2002, FEBS letters.

Proscillaridin A exerts anti-tumor effects through GSK3β activation and alteration of microtubule dynamics in glioblastoma

D. Figarella-Branger, R. Berges, D. Braguer, 2018, Cell Death & Disease.

Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway.

E. Pasquier, M. Carré, D. Braguer, 2004, Molecular cancer therapeutics.

Opposite effects of antimicrotubule agents on c-myc oncogene expression depending on the cell lines used.

D. Braguer, V. Bourgarel-Rey, C. Briand, 2000, European journal of cancer.

Tau protein is involved in the apoptotic process induced by anti-microtubule agents on neuroblastoma cells

D. Braguer, C. Briand, M. Remacle-Bonnet, 1999, Apoptosis.

The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells

H. Lane, D. Figarella-Branger, R. Berges, 2016, Molecular Cancer Therapeutics.

Microtubule-targeting agents in angiogenesis: where do we stand?

E. Pasquier, D. Braguer, S. Honoré, 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites

A. Kruczynski, D. Braguer, V. Bourgarel-Rey, 2008, Molecular Cancer Therapeutics.

Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth.

S. Knapp, A. di Pietro, C. Nguyen, 2012, Cancer research.

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

Pierre-Marie Martin, Sophie Lancelot, Diane Braguer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug‐induced apoptosis in neuroblastoma cells

D. Braguer, A. Delacourte, D. Braguer, 2001, Journal of neuroscience research.

End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo

O. Chinot, D. Figarella-Branger, A. Kruczynski, 2014, Oncotarget.

Negative regulation of EB1 turnover at microtubule plus ends by interaction with microtubule-associated protein ATIP3

D. Braguer, L. Serre, I. Arnal, 2015, Oncotarget.

The Glutamine-rich Region of the HIV-1 Tat Protein Is Involved in T-cell Apoptosis*

Eddy Pasquier, Diane Braguer, Pontiano Kaleebu, 2004, Journal of Biological Chemistry.

HIV-1 Tat protein enhances Microtubule polymerization

M. Carré, D. Braguer, P. Barbier, 2005, Retrovirology.

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

O. Chinot, D. Figarella-Branger, D. Braguer, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MVL-PLA2, a Snake Venom Phospholipase A2, Inhibits Angiogenesis through an Increase in Microtubule Dynamics and Disorganization of Focal Adhesions

E. Pasquier, D. Braguer, M. Ayeb, 2010, PloS one.

Comparative effects of taxol and Taxotere on two different human carcinoma cell lines

I. Barasoain, D. Braguer, C. Briand, 1994, Cancer Chemotherapy and Pharmacology.

Hydrophilic Fluorescent Nanoprodrug of Paclitaxel for Glioblastoma Chemotherapy

D. Braguer, M. Blanchard‐Desce, A. Lazar, 2019, ACS omega.

Formulation of a flush solution of heparin, vancomycin, and colistin for implantable access systems in oncology

M. Drancourt, D. Braguer, P. Guillet, 1997 .

Chemical modifications of imidazole-containing alkoxyamines increase C-ON bond homolysis rate: Effects on their cytotoxic properties in glioblastoma cells.

M. Carré, C. Chacon, D. Braguer, 2019, Bioorganic & medicinal chemistry.

Identification of an ascorbic acid metabolite among "uremic middle molecules".

D. Braguer, Y. Berland, J. Monti, 1990, Clinical chemistry.

Qualitative study of the interaction mechanism of estrogenic drugs with tubulin.

D. Braguer, V. Peyrot, A. Crevat, 1991, Biochemical pharmacology.

Partial Depletion of Gamma-Actin Suppresses Microtubule Dynamics

D. Braguer, M. Kavallaris, S. Honoré, 2013, Cytoskeleton.

[Study impacto: Descriptive analyzis of pharmacist's clinical practice in onco-hematology].

F. Pinguet, D. Braguer, J. Vigneron, 2015, Annales Pharmaceutiques Françaises.

Pretreatment by tubulin agents decreases C-MYC induction in human colon carcinoma cell line HT29-D4.

D. Braguer, C. Briand, D Braguer, 1997, Biochemical and biophysical research communications.

Seventy‐two‐hour stability of Taxol® in 5% dextrose or 0·9% sodium chloride in Viaflo®, Freeflex®, Ecoflac® and Macoflex N® non‐PVC bags

D. Braguer, C. Solas, B. Lacarelle, 2005, Journal of clinical pharmacy and therapeutics.

Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals

O. Blin, J. Pouget, D. Braguer, 2011, Fundamental & clinical pharmacology.

Laser- synthesized TiN nanoparticles as promising plasmonic alternative for biomedical applications

A. da Silva, A. Kabashin, B. Larrat, 2019, Scientific Reports.

Identification of two uremic toxins by nuclear magnetic resonance and mass spectrometry.

D. Braguer, J. Monti, C. Durand, 1987, Advances in experimental medicine and biology.

MALDI in-source decay of high mass protein isoforms: application to alpha- and beta-tubulin variants.

D. Calligaris, D. Braguer, D. Lafitte, 2010, Analytical chemistry.

Microtubule targeting agents: from biophysics to proteomics

C. Villard, D. Braguer, D. Calligaris, 2010, Cellular and Molecular Life Sciences.

Tubulin proteomics: towards breaking the code.

R. Angeletti, E. Pasquier, D. Braguer, 2009, Analytical biochemistry.

ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics.

A. Vincent-Salomon, O. Delattre, F. André, 2013, Cancer research.

Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices

Iseult Lynch, Markus Berges, Vicki Stone, 2011, Nanotoxicology.

Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics

D. Braguer, C. Briand, M. Jordan, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells

N. André, E. Pasquier, K. MacKenzie, 2012, Angiogenesis.

Memo–RhoA–mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells

D. Isnardon, D. Braguer, Kossay Zaoui, 2008, The Journal of cell biology.

Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine

D. Arango, M. Carré, D. Braguer, 2006, Anti-cancer drugs.

Inhibition of microtubule formation by uremic toxins: action mechanism and hypothesis about the active component.

D. Braguer, J. Monti, P. Gallice, 1986, Clinical nephrology.

Abstract 1977: BAL27862: A unique microtubule-targeted drug that suppresses microtubule dynamics, severs microtubules, and overcomes Bcl-2- and tubulin subtype-related drug resistance

H. Lane, D. Braguer, F. Bachmann, 2010 .

ROS-mediated EB1 phosphorylation through Akt/GSK3β pathway: implication in cancer cell response to microtubule-targeting agents

Amandine Rovini, Diane Braguer, M. Carré, 2014, Oncotarget.

Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter.

Jean Imbert, Diane Braguer, A. Savry, 2009, Biochemical pharmacology.

Ultrapure laser-synthesized Si nanoparticles with variable oxidation states for biomedical applications.

Marc Sentis, Andrei V. Kabashin, Victor Yu. Timoshenko, 2016, Journal of materials chemistry. B.

Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.

E. Pasquier, A. Kruczynski, D. Braguer, 2006, Cancer research.

In vitro inhibition of microtubule assembly by disulfiram.

D. Braguer, V. Peyrot, A. M. Chauvet-monges, 1986, International journal of clinical pharmacology, therapy, and toxicology.

31P nuclear magnetic resonance study of variations in intra-erythrocytic ATP concentration and pH induced by surgical trauma.

D. Braguer, J. Monti, A. Crevat, 1987, Clinical chemistry.

31PNuclearMagneticResonanceStudyof Variationsin lntra-ErythrocyticATP Concentration and pH Inducedby SurgicalTrauma

D. Braguer, S. Martinez, Jean PierreMontl, 1987 .

Ascorbic Acid Derivatives in Two Different Fractions of Uremic Toxins

D. Braguer, Y. Berland, J. Monti, 1991, The International journal of artificial organs.

[Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer].

D. Braguer, R. Laugier, J. Seitz, 2007, Gastroenterologie clinique et biologique.

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

E. Pasquier, O. Chinot, D. Figarella-Branger, 2023, EBioMedicine.

HIV-1 Tat protein enhances Microtubule polymerization

M. Carré, D. Braguer, P. Barbier, 2015 .

Comparison of pharmacokinetics and biodistribution of laser-synthesized plasmonic Au and TiN nanoparticles

A. Kabashin, D. Braguer, S. Deyev, 2021, Journal of Physics: Conference Series.

Delaying Anticancer Drug Delivery by Self-Assembly and Branching Effects of Minimalist Dendron-Drug Conjugates.

D. Braguer, M. Roy, M. Gingras, 2018, Chemistry.

Phase II study of temozolomide (TMZ) administered on a 7 days on-7 days off regimen as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM)

J. Peragut, O. Chinot, D. Figarella-Branger, 2005 .

In-situ temperature monitoring with photoacoustics during photothermal therapy and perspectives for glioblastoma treatment monitoring

A. V. Kabashin, K. Metwally, C. Bastiancich, 2019, European Conference on Biomedical Optics.

HIV-1 Tat protein enhances Microtubule polymerization

M. Carré, D. Braguer, P. Barbier, 2005, Retrovirology.

Memo–RhoA–mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells

D. Isnardon, D. Braguer, Kossay Zaoui, 2008, The Journal of cell biology.

Tumor and Stem Cell Biology ATIP 3 , a Novel Prognostic Marker of Breast Cancer Patient Survival , Limits Cancer Cell Migration and Slows Metastatic Progression by Regulating Microtubule Dynamics

A. Vincent-Salomon, O. Delattre, D. Braguer, 2013 .